Mitochondrial DNA mutations drive aerobic glycolysis to enhance checkpoint blockade response in melanoma

Area of Science:

• Oncology
• Cancer Metabolism
• Mitochondrial Biology

Background:

• Mitochondrial DNA (mtDNA) mutations are common in tumors but their functional impact remains debated.
• mtDNA encodes critical components of oxidative phosphorylation and cellular metabolism.
• Understanding mtDNA's role in tumor biology is crucial for cancer treatment strategies.

Purpose of the Study:

• To investigate the functional consequences of engineered mtDNA mutations in melanoma.
• To determine if mtDNA mutations influence tumor microenvironment and immune response.
• To assess the therapeutic potential of mtDNA mutations in cancer treatment.

Main Methods:

• Engineered truncating mutations in the mtDNA-encoded Mt-Nd5 gene in murine melanoma models.
• Analyzed metabolic shifts (Warburg-like) and tumor microenvironment changes.
• Assessed anti-tumor immune responses, including neutrophil presence and redox balance.
• Correlated mtDNA mutation heteroplasmy with patient response to checkpoint blockade therapy.

Main Results:

• Engineered mtDNA mutations induced a Warburg-like metabolic shift and altered tumor microenvironments.
• mtDNA mutations elicited an anti-tumor immune response characterized by neutrophil loss.
• Tumors with mtDNA mutations showed enhanced sensitivity to checkpoint blockade therapy in a neutrophil-dependent manner.
• Patient tumors with high mtDNA mutation heteroplasmy exhibited a 2.5-fold improved response rate to checkpoint blockade.

Conclusions:

• mtDNA mutations functionally regulate cancer metabolism and tumor biology.
• mtDNA mutations can reshape the tumor microenvironment and elicit anti-tumor immunity.
• mtDNA mutations represent a potential biomarker for predicting response to checkpoint blockade therapy.
• Targeting mtDNA mutations may offer novel therapeutic strategies and improve treatment stratification in cancer.